Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Found 7361 matches for

An internationally recognised centre of excellence for biomedical and clinical research and teaching

Exploring the health impacts of climate change

In a new study, published in Nature Reviews Endocrinology, endocrinologists and researchers from the Nuffield Department of Women’s & Reproductive Health (NDWRH) at the University of Oxford, the London School of Hygiene & Tropical Medicine, the William Harvey Research Institute (WHRI) at Queen Mary University of London and the National University of Singapore have emphasised the critical need for further research into the effects of heat exposure on the endocrine system.

Active Surveillance Patients International honours ProtecT Trial for pioneering research demonstrating the safety of active surveillance

The ProtecT Trial has been named the 2024 recipient of the Active Surveillance Patients International (ASPI) Special Award for game-changing research in the development of the Active Surveillance approach to managing low-risk prostate cancer.

Long-term cognitive and psychiatric effects of COVID-19 revealed in new study

Many people who were hospitalised with COVID-19 continue to have cognitive and psychiatric problems even two to three years post-infection, according to a new study published in Lancet Psychiatry.

The scale of Long COVID: New study highlights the widespread impact

A comprehensive state-of-the-art review published today in The Lancet has revealed the widespread impact of Long COVID, providing crucial insights into the condition's biological mechanisms and outlining key areas for future research.

Tech transfer partnership between universities creates company to transform care for millions of women

Amber Therapeutics (Tx), a start-up involving the University of Oxford, has just completed a $100 million Series A funding round from healthcare and technology investors in the US and UK to develop treatment for mixed urinary incontinence.

The Oxford students at the forefront of the fight against microbial resistance

Antimicrobial resistance (AMR) is one the most pressing challenges facing the world today. Common infections that were once easily treated by antibiotics are becoming life-threatening again. By 2050 it is predicted that over 10 million deaths will be caused by drug-resistant infections every year.

New Oxford quantum hub to tackle key challenges in quantum technologies

Today, the UK Government has announced the launch of five new research hubs to develop quantum technologies in areas ranging from healthcare and computing to national security and critical infrastructure. One of the hubs will be led by the University of Oxford, and aims to develop the technologies needed for the UK to play a key role in the development of quantum computers - a market estimated to be worth $1.3 trillion by 2035.

New shingles vaccine could reduce risk of dementia

The new recombinant shingles vaccine ‘Shingrix’ is associated with a reduced risk of dementia compared to an earlier shingles vaccine, according to a major new study published in Nature Medicine. It is also more protective than vaccines against other infections.

Future of Oxford lactation research centre secured with £9.12 million donation

A £9.12 million gift from the Family Larsson-Rosenquist Foundation has endowed an Oxford University research centre investigating the role of hormones in human milk production.

The Oxford Respiratory Trials Unit awarded £2.8m to study treatment for pleural infection

The Oxford Respiratory Trials Unit (ORTU) at the Nuffield Department of Medicine has been awarded a £2.8 million grant from the National Institute for Health and Care Research Health Technology Assessment (NIHR HTA) to conduct the MIST4 study.

Shorter life expectancy during COVID-19 for India’s marginalised

A new paper published in Science Advances finds that life expectancy in India was 2.6 years lower in 2020 than 2019, with women and marginalised social groups suffering the greatest declines.

Three hospital trusts participating in an Oxford-led study evaluating AI software for diagnosing prostate cancer in clinical settings

Oxford University Hospitals (OUH) NHS Foundation Trust, North Bristol NHS Trust, and University Hospitals Coventry and Warwickshire (UHCW) NHS Trust are evaluating a new Artificial Intelligence (AI) diagnostic system that could help improve prostate cancer diagnosis.

Apollo Therapeutics and Oxford University enter into drug discovery and development collaboration

The University of Oxford and Apollo Therapeutics, a portfolio biopharmaceutical company, announce the signing of a drug discovery and development collaboration aimed at translating breakthroughs made by biomedical researchers at Oxford.

Centre to address global epilepsy challenges launched at Oxford’s Wolfson College

The University of Oxford is launching The Centre for Global Epilepsy to address the global burden of epilepsy, particularly in lower-income countries.

Oxford success in the 2024 Lasker Essay Contest

Subashan Vadibeler, a recent Oxford Rhodes scholar and Department of Oncology student, is one of five co-winners of the international 2024 Lasker Essay Contest, sponsored by the Lasker Foundation.

Yellowstone Biosciences spinout launches to advance cutting-edge cancer therapies

Yellowstone Biosciences, a biotechnology spinout, has launched to pioneer new cancer treatments using advanced T-cell therapies based on ground-breaking research from the MRC Weatherall Institute of Molecular Medicine at University of Oxford.

Côte d’Ivoire makes history as first nation to deploy R21/Matrix-M™ Malaria Vaccine

Today marks the official rollout of the new R21/Matrix-M™ malaria vaccine - co-developed by the University of Oxford and Serum Institute of India, leveraging Novavax’s Matrix-M™ adjuvant technology. In a historic step in the battle to beat malaria, the first official vaccination is due to take place in Abidjan, Côte d’Ivoire, this morning and will be subsequently rolled-out in 38 districts across the country.

COVID-19 phone apps shown to provide real-time information on the spread of infectious diseases

Researchers analysing data from mobile phone apps used during the COVID-19 pandemic found that digital contact tracing provides rich insights into epidemic dynamics with unprecedented resolution and speed, revealing how transmission varied by day of the week, gatherings during the 2021 Christmas period, and the UEFA Euro football tournament in July 2021

Open Access Updates

Oxford University research showcased at the 2024 Royal Society Summer Science Exhibition

University of Oxford research will be on display at the Royal Society’s flagship public engagement event, the Summer Science Exhibition, which launches this year on Tuesday 2 July in central London. This historic annual event, which has been running for more than 200 years, expects to attract more than 10,000 visitors seeking the latest cutting-edge science.

Load More